Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cardiovascular risks in hemophilia A

Humphries TJ et al. Adv Med Sci. 2018;63(2):329-33

Key clinical point: Concerns may be unfounded about risks of earlier-onset cardiovascular disease in men with hemophilia A.

Major finding: Prevalence rates of diabetes (P = .0108) and hyperlipidemia (P = .0001) were higher in the control group, compared with patients with hemophilia A.

Study details: A retrospective chart review involving 74 men with hemophilia A and 222 men without the condition, matched by study year, payer type, race, and age.

Disclosures: The study was funded by Bayer. Three authors were employed by Bayer when the study was conducted. Other authors reported employment by Xcenda and the Henry Ford Health System and research funding from Xcenda.

Read the article here.


Humphries TJ et al. Adv Med Sci. 2018;63(2):329-33.

This Week's Must Reads

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44.

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Must Reads in Bleeding Disorders

FDA draft guidance on platelet safety, FDA Draft Guidance, December 2018

HemoTypeSC offers rapid sickle cell detection, Serrao E et al. ASH 2018, Abstract LBA-3

Impact of RBC transfusion limits, Roubinian NH et al. Ann Intern Med. 2018 Dec 18. doi: 10.7326/M17-3253

Early results for novel hemophilia A infusion, Chowdary P et al. ASH 2018, Abstract 489

Diagnostic challenges in hemophilia A, Patil R et al. Thromb Res. 2018 Dec;172:29-35